# Healthcare & Pharmaceuticals Procurement Policy

## 1. Overview
This policy governs the procurement of pharmaceuticals, medical devices, medical supplies, and healthcare equipment, ensuring compliance with FDA regulations, patient safety, and quality standards.

## 2. Regulatory Framework

### 2.1 Mandatory Compliance
- **FDA Regulations**: 21 CFR Parts 11, 210, 211, 820
- **Good Manufacturing Practice (GMP)**: Current GMP compliance
- **ISO 13485**: Medical devices quality management
- **HIPAA**: Patient data protection
- **DEA**: Controlled substances (if applicable)

### 2.2 International Standards
- **EU MDR/IVDR**: For European markets
- **WHO GMP**: For global operations
- **ICH Guidelines**: For pharmaceutical development
- **MDSAP**: Medical Device Single Audit Program

## 3. Supplier Selection Criteria

### 3.1 Mandatory Requirements
- **Certifications Required**:
  - FDA registration and listing
  - GMP certification
  - ISO 13485 (for medical devices)
  - ISO 9001 (Quality Management)
- **Regulatory Standing**: No warning letters or import alerts
- **Quality Rating**: Minimum 4.7/5.0
- **Audit Rights**: Allow on-site audits

### 3.2 Preferred Qualifications
- Vertical integration and API manufacturing
- Global regulatory approvals
- Track record of supply reliability
- Pharmacovigilance capabilities
- Cold chain management (for biologics)

## 4. Product Categories

### 4.1 Pharmaceuticals
- **Approved Suppliers**: Pfizer, Johnson & Johnson, Novartis, Roche, Merck
- **Quality Requirements**:
  - Certificate of Analysis (CoA) for each batch
  - Stability data
  - Impurity profiles
  - Dissolution testing results
- **Lead Time**: 14-21 days (standard), 90-180 days (custom)
- **Minimum Order**: Varies by product
- **Payment Terms**: Net 90 days

### 4.2 Medical Devices
- **Approved Suppliers**: Medtronic, Boston Scientific, Siemens Healthineers, GE Healthcare
- **Quality Requirements**:
  - 510(k) clearance or PMA approval
  - UDI (Unique Device Identification)
  - Biocompatibility testing
  - Sterilization validation
- **Warranty**: Minimum 1 year, 5 years for capital equipment
- **Service**: 24/7 support for critical devices

### 4.3 Medical Supplies
- **Categories**: Surgical supplies, PPE, consumables, diagnostics
- **Approved Suppliers**: Cardinal Health, McKesson, Medline, Owens & Minor
- **Quality Requirements**:
  - Sterility assurance (SAL 10^-6)
  - Lot traceability
  - Expiry date management
  - Recall procedures
- **Lead Time**: 5-10 days
- **Payment Terms**: Net 60 days

## 5. Procurement Process

### 5.1 Approval Workflow
- **Under $50,000**: Pharmacy/Clinical Director approval
- **$50,000-$250,000**: VP Clinical + Finance approval
- **$250,000-$1,000,000**: CMO + CFO approval
- **Over $1,000,000**: Executive Committee + Board approval

### 5.2 Vendor Evaluation
1. Regulatory compliance and quality (40%)
2. Clinical efficacy and safety (25%)
3. Pricing and value (20%)
4. Supply reliability (10%)
5. Technical support (5%)

### 5.3 New Product Introduction
- Clinical evaluation and formulary review
- P&T (Pharmacy & Therapeutics) Committee approval
- Pilot testing and validation
- Staff training requirements
- Integration with existing systems

## 6. Quality Assurance

### 6.1 Incoming Inspection
- 100% visual inspection
- Statistical sampling for testing (per USP/Ph. Eur.)
- Identity testing for all active ingredients
- Sterility testing for sterile products
- Quarantine until release

### 6.2 Testing Requirements
- **Pharmaceuticals**: Identity, assay, impurities, dissolution
- **Medical Devices**: Functionality, sterility, packaging integrity
- **Biologics**: Potency, purity, endotoxin, bioburden

### 6.3 Quality Metrics
- **Defect Rate**: Zero tolerance for critical defects
- **Batch Rejection Rate**: <0.1%
- **On-Time Delivery**: 98% minimum
- **Documentation Accuracy**: 100%

## 7. Risk Management

### 7.1 Patient Safety
- Medication error prevention
- Adverse event reporting
- Product recall procedures
- Risk-benefit analysis for new products

### 7.2 Supply Chain Risks
- **Single Source Risk**: Dual sourcing for critical drugs
- **Shortage Management**: 90-180 day safety stock
- **Counterfeit Prevention**: Serialization and track-and-trace
- **Cold Chain**: Temperature monitoring and validation

### 7.3 Regulatory Risks
- Continuous monitoring of FDA communications
- Supplier audit program
- Change control procedures
- Regulatory intelligence

## 8. Compliance & Traceability

### 8.1 Serialization
- Unit-level serialization for prescription drugs
- Aggregation for shipping containers
- EPCIS data exchange
- Verification system integration

### 8.2 Lot Traceability
- Batch/lot number tracking
- Expiry date management
- FEFO (First Expired, First Out) inventory management
- Recall readiness (6-hour response)

### 8.3 Documentation
- Device History Record (DHR)
- Batch Manufacturing Record (BMR)
- Certificate of Analysis (CoA)
- Regulatory submissions
- Audit trails (21 CFR Part 11 compliant)

## 9. Sustainability & Ethics

### 9.1 Environmental Standards
- Pharmaceutical waste management
- Green chemistry principles
- Sustainable packaging
- Carbon footprint reduction

### 9.2 Ethical Sourcing
- No animal testing (where alternatives exist)
- Ethical clinical trials
- Access to medicines programs
- Transparent pricing

### 9.3 ESG Scoring
- Minimum sustainability score: 9.5/10
- Annual ESG audits
- Patient access initiatives
- Community health programs

## 10. Pricing & Reimbursement

### 10.1 Pricing Strategies
- Formulary tier placement
- Rebate and chargeback agreements
- Value-based pricing
- Biosimilar/generic substitution

### 10.2 Cost Containment
- Therapeutic interchange programs
- Utilization management
- Waste reduction initiatives
- Group purchasing organization (GPO) participation

### 10.3 Reimbursement
- Insurance coverage verification
- Prior authorization management
- Patient assistance programs
- Specialty pharmacy coordination

## 11. Clinical Governance

### 11.1 Formulary Management
- Evidence-based selection
- P&T Committee review
- Clinical guidelines alignment
- Therapeutic equivalence evaluation

### 11.2 Clinical Trials
- Investigational drug procurement
- GCP compliance
- Informed consent
- IRB/Ethics Committee approval

## 12. Vendor Management

### 12.1 Supplier Audits
- Pre-qualification audits
- Annual surveillance audits
- For-cause audits
- Third-party audit acceptance

### 12.2 Performance Monitoring
- Monthly quality metrics
- Quarterly business reviews
- Annual supplier scorecards
- Continuous improvement plans

### 12.3 Relationship Management
- Dedicated account management
- Medical science liaison (MSL) support
- Clinical education programs
- Product pipeline discussions

## 13. Emergency Procurement

### 13.1 Drug Shortages
- FDA shortage database monitoring
- Alternative product identification
- Therapeutic substitution protocols
- Compounding (as last resort)

### 13.2 Emergency Use Authorization (EUA)
- Pandemic preparedness
- Expedited approval process
- Safety monitoring
- Post-market surveillance

## 14. Technology Integration

### 14.1 Systems Integration
- EHR/EMR integration
- Pharmacy management systems
- Inventory management
- Automated dispensing cabinets

### 14.2 Data Analytics
- Utilization patterns
- Adverse event tracking
- Cost analysis
- Predictive analytics for demand

## 15. Training & Education

### 15.1 Staff Training
- Product-specific training
- Regulatory compliance
- Safety protocols
- Technology systems

### 15.2 Continuing Education
- Clinical updates
- New product launches
- Regulatory changes
- Best practices

## 16. Documentation Requirements

### 16.1 Mandatory Documentation
- FDA registration certificates
- GMP certificates
- Certificates of Analysis (CoA)
- Stability data
- Validation reports
- Audit reports
- Recall procedures
- Pharmacovigilance agreements

## 17. Product Recalls

### 17.1 Recall Classification
- Class I: Serious health hazard
- Class II: Temporary health problem
- Class III: No health hazard

### 17.2 Recall Procedures
- Immediate quarantine
- Customer notification (24 hours)
- Root cause investigation
- Corrective actions
- FDA reporting

## 18. Controlled Substances

### 18.1 DEA Requirements
- DEA registration
- Secure storage
- Perpetual inventory
- Biennial inventory
- Theft/loss reporting

### 18.2 Opioid Stewardship
- Prescription monitoring
- Abuse-deterrent formulations
- Disposal programs
- Addiction treatment resources

## 19. Exceptions & Waivers

### 19.1 Exception Process
- Clinical justification required
- P&T Committee review
- CMO approval
- Time-limited exceptions
- Patient safety assessment

---

**Policy Owner**: Chief Medical Officer (CMO) & VP Pharmacy
**Review Frequency**: Annual (or upon regulatory changes)
**Last Updated**: December 2024
**Version**: 2.0
